Header Logo

Connection

MICHAEL JAMES OVERMAN to Neoplasms

Back to Details
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Neoplasms.
MICHAEL JAMES OVERMAN
Connection Strength
1.149
Neoplasms
  1. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol. 2023 04 20; 41(12):2181-2190.
    View in: PubMed
    Score: 0.135
  2. Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. JAMA Oncol. 2019 03 01; 5(3):402-405.
    View in: PubMed
    Score: 0.104
  3. Underreporting of Research Biopsies from Clinical Trials in Oncology. Clin Cancer Res. 2017 Nov 01; 23(21):6450-6457.
    View in: PubMed
    Score: 0.093
  4. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med. 2016 Feb; 5(2):239-47.
    View in: PubMed
    Score: 0.083
  5. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol. 2015 Nov 01; 33(31):3583-90.
    View in: PubMed
    Score: 0.081
  6. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol. 2013 Jan 01; 31(1):17-22.
    View in: PubMed
    Score: 0.067
  7. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct; 26(8):794-9.
    View in: PubMed
    Score: 0.050
  8. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. 2008 Oct; 26(5):445-54.
    View in: PubMed
    Score: 0.049
  9. Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials. JAMA Netw Open. 2023 05 01; 6(5):e2313819.
    View in: PubMed
    Score: 0.035
  10. Integration of Remote Symptom and Biometric Monitoring Into the Care of Adult Patients With Cancer Receiving Chemotherapy-A Decentralized Feasibility Pilot Study. JCO Oncol Pract. 2023 06; 19(6):e811-e821.
    View in: PubMed
    Score: 0.034
  11. Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection. Sci Transl Med. 2022 08 10; 14(657):eabo7604.
    View in: PubMed
    Score: 0.033
  12. Active surveillance of chemotherapy-related symptom burden in ambulatory cancer patients via the implementation of electronic patient-reported outcomes and sensor-enabled vital signs capture: protocol for a decentralised feasibility pilot study. BMJ Open. 2022 04 05; 12(4):e057693.
    View in: PubMed
    Score: 0.032
  13. Understanding Suboptimal Response to Immune Checkpoint Inhibitors. Adv Biol (Weinh). 2023 04; 7(4):e2101319.
    View in: PubMed
    Score: 0.032
  14. Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial. J Pain Symptom Manage. 2021 08; 62(2):223-232.e1.
    View in: PubMed
    Score: 0.029
  15. Trials of locoregional therapies inspired by SABR-COMET. Lancet. 2020 10 03; 396(10256):956-957.
    View in: PubMed
    Score: 0.029
  16. Durability of partial splenic artery embolization on platelet counts for cancer patients with hypersplenism-related thrombocytopenia. Abdom Radiol (NY). 2020 09; 45(9):2886-2894.
    View in: PubMed
    Score: 0.029
  17. Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. JAMA Netw Open. 2020 07 01; 3(7):e207911.
    View in: PubMed
    Score: 0.028
  18. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol. 2020 07; 31(7):861-872.
    View in: PubMed
    Score: 0.028
  19. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080.
    View in: PubMed
    Score: 0.028
  20. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol. 2020 01 20; 38(3):214-222.
    View in: PubMed
    Score: 0.027
  21. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev. 2018 09; 37(2-3):439-454.
    View in: PubMed
    Score: 0.025
  22. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21.
    View in: PubMed
    Score: 0.020
  23. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J. 2014 Jan-Feb; 20(1):8-14.
    View in: PubMed
    Score: 0.018
  24. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2014 May; 22(5):1223-31.
    View in: PubMed
    Score: 0.018
  25. Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites. Ann Surg Oncol. 2013 Feb; 20(2):497-505.
    View in: PubMed
    Score: 0.017
  26. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011 Oct 01; 17(19):6130-9.
    View in: PubMed
    Score: 0.015
  27. Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials. Cancer Res Commun. 2024 Aug 01; 4(8):2183-2188.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.